Organ/region of interest
SUVmax (mean ± SD)
Spleen
28.8 ± 12.5
Renal cortex
12.8 ± 3.4
Liver
11.6 ± 3.8
Blood pool
2.3 ± 1.1
3.2 Postpancreatectomy SSTR PET/CT Pre PRRNT
The mean SUVmax of the splenosis (10.5 ± 4.3) measured in 10 patients was found to be about one-third of that of normal spleen (as measured on initial staging SSTR PET/CT).
3.3 Restaging SSTR PET/CT Post PRRNT
The results of restaging SSTR PET/CT performed 4–7 months after a subsequent cycle of PRRNT were available in seven patients at time of this study. Three of these patients had stable disease, two had partial remission, and two had progressive disease. The size and SUVmax of splenosis and previously known metastases in the abdomen (abdominal lymph nodes and liver lesions) on pretherapy SSTR PET/CT were compared with the values on posttherapy SSTR PET/CT in seven patients (Table 2). While there was a significant change in the size and SUVmax of the metastases in the abdominal lymph nodes and liver, there was no significant change in the size or SUVmax of splenosis, on the posttherapy follow-up SSTR PET/CT in seven patients (Fig. 1).
Table 2
Comparison between size (longest diameter) and SUVmax of metastases and splenosis on pre- and post-PRRNT SSTR PET/CT
Region of interest | No. | Pretherapy size (mean ± SD) cm | Posttherapy size (mean ± SD) cm | p-Value (size) | Pretherapy SUVmax (mean ± SD) | Posttherapy SUVmax (mean ± SD) | p-Value (SUVmax) |
|---|---|---|---|---|---|---|---|
Metastases | 33 | 5.3 ± 2.1 | 4.7 ± 2.2 | 0.034 | 29.2 ± 13.8 | 21.8 ± 12.4 | 0.018 |
Splenosis | 7 | 2.8 ± 1.3 | 2.9 ± 1.2 | >0.05 | 10.5 ± 4.3 | 11.2 ± 5.6 | >0.05 |
Fig. 1
via Cation Exchange Cartridges: Versatile Options
Experience in Peptide Receptor Radionuclide Therapy
Intermediate-Affinity Monoclonal Antibodies Targeting EGFR and HER2/c-neu: Preparation and Preclinical Evaluation
Novel 68Ga-Labeled Pteroic Acid-Based PET Tracer for Tumor Imaging via the Folate Receptor
Rare Case of a Large Spinal Meningioma with Mediastinal Extension and Malignant Behavior Classified Histologically as Benign
Role of 68Ga-Labeled Somatostatin Analogs in the Workup of Patients with NETs: AIIMS Experience
68Ga-DOTATOC PET/CT (MIP image on the left, coronal fused image in the middle, and transverse CT and fused images on the right; upper row shows images acquired before PRRNT, and lower row shows images acquired 4 months after a cycle of PRRNT) in a patient after splenectomy demonstrating splenosis (arrows); no change in size and no significant change in SUVmax of splenosis was noted before and after PRRNT
Related posts:
via Cation Exchange Cartridges: Versatile Options
Experience in Peptide Receptor Radionuclide Therapy
Intermediate-Affinity Monoclonal Antibodies Targeting EGFR and HER2/c-neu: Preparation and Preclinical Evaluation
Novel 68Ga-Labeled Pteroic Acid-Based PET Tracer for Tumor Imaging via the Folate Receptor
Rare Case of a Large Spinal Meningioma with Mediastinal Extension and Malignant Behavior Classified Histologically as Benign
Role of 68Ga-Labeled Somatostatin Analogs in the Workup of Patients with NETs: AIIMS Experience
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
